REVIEW ARTICLE

Advancements in Rapid Detection Technologies for Club Drugs in Beverages

Uday Kumar P*, Dharani S, Divya P, Mounika T

PG Scholar, A.U College of Pharmaceutical Sciences, Visakhapatnam, Andhra Pradesh, India

Publication history: Received on 30th July; Revised on 7th August; Accepted on 17th August 2024

Article DOI: 10.69613/5h65gt50

Abstract: The rising incidence of drug-facilitated crimes, particularly sexual assaults, has heightened the need for efficient and accessible detection methods for club drugs in beverages. This review article discusses about the recent developments in sensor-based technologies designed to identify common date rape drugs, including benzodiazepines, gamma-hydroxybutyric acid (GHB), ketamine, and their analogs. We discuss the evolution from traditional analytical methods to more portable and user-friendly solutions, focusing on microfluidic paper-based analytical devices (μPADs), electrochemical sensors, and colorimetric assays. The integration of these technologies with smartphone applications and machine learning algorithms has significantly enhanced their practicality for real-time, on-site detection. We evaluate the sensitivity, specificity, and ease of use of various detection methods, highlighting their potential for widespread implementation in social settings. Additionally, we address the challenges associated with detecting multiple drugs simultaneously and the ongoing efforts to minimize false positives. The review also considers the legal and ethical implications of using such devices in public spaces. Finally, we outline future research directions, including the development of wearable sensors and the application of nanotechnology to further improve detection capabilities. This review aims to inform researchers, healthcare professionals, and policymakers about the current state and future potential of club drug detection technologies in combating drug-facilitated crimes.

Keywords: Club drugs; Date rape drugs; Microfluidic sensors; Electrochemical detection; Colorimetric assays; Portable diagnostics

1. Introduction

Drug-facilitated crimes, particularly drug-facilitated sexual assault (DFSA), have become an increasingly significant concern in society. These crimes involve the surreptitious administration of psychoactive substances to victims, often rendering them incapable of giving consent or resisting assault [1]. The prevalence of such crimes has risen alarmingly over the past decades, with studies indicating that up to 20% of sexual assaults may involve the use of drugs or alcohol [2]. The perpetrators of these crimes typically exploit the pharmacological properties of certain substances to incapacitate their victims. These drugs often induce effects such as sedation, amnesia, and muscle relaxation, making victims vulnerable and less likely to resist or remember the assault [3]. The covert nature of drug administration, often in social settings like bars or parties, compounds the challenge of prevention and detection [4].

Historically, the recognition of drug-facilitated crimes as a distinct category of offense emerged in the late 20th century. The term "date rape drugs" gained prominence in the 1990s, coinciding with increased awareness of substances like flunitrazepam (Rohypnol) being used for criminal purposes [5]. This recognition led to legal and policy responses, such as the Drug-Induced Rape Prevention and Punishment Act in the United States, which imposed stricter penalties for the use of drugs in sexual assaults [6]. The global scale of this issue has prompted international organizations to take action. The World Health Organization has highlighted the role of drugs in sexual violence, while the United Nations Office on Drugs and Crime has emphasized the need for improved detection and prevention strategies [7]. Despite these efforts, the true extent of drug-facilitated crimes remains difficult to quantify due to underreporting, rapid metabolism of drugs in the body, and the challenges in proving drug administration in legal contexts [8].

1.1. Common Club Drugs and Their Effects

The term "club drugs" encompasses a range of substances frequently associated with drug-facilitated crimes. These drugs are often chosen for their ability to dissolve easily in beverages, their lack of taste or odor, and their rapid onset of action. Some of the most commonly encountered club drugs include:

* Corresponding author: Uday Kumar P

1.1.1. Gamma-Hydroxybutyric Acid (GHB) and Gamma-Butyrolactone (GBL)

GHB, often referred to as "liquid ecstasy," is a central nervous system depressant. It produces effects ranging from euphoria and increased sociability at low doses to unconsciousness and amnesia at higher doses [9]. GBL, a prodrug of GHB, is rapidly converted to GHB in the body. Both substances are colorless and slightly salty, making them difficult to detect in drinks. Effects typically onset within 15-30 minutes and can last for 3-6 hours [10].

1.1.2. Benzodiazepines

This class includes drugs like flunitrazepam (Rohypnol), diazepam, and alprazolam. Benzodiazepines enhance the effect of the neurotransmitter GABA, resulting in sedation, muscle relaxation, and anterograde amnesia [11]. Flunitrazepam, in particular, has been heavily associated with drug-facilitated crimes. Its effects can begin within 30 minutes of ingestion and last for several hours [12].

1.1.3. Ketamine

Originally developed as an anesthetic, ketamine produces dissociative effects and hallucinations. In the context of drug-facilitated crimes, it can cause confusion, amnesia, and immobilization. The onset of effects is rapid, often within minutes of ingestion, and can last for 1-2 hours [13].

1.1.4. Alcohol

While not typically categorized as a club drug, alcohol remains one of the most common substances involved in drug-facilitated crimes. It impairs judgment, reduces inhibitions, and can cause blackouts at high doses. The synergistic effects of alcohol with other drugs can significantly amplify the risk of incapacitation [14].

1.1.5. Novel Psychoactive Substances (NPS)

The landscape of club drugs is constantly evolving with the emergence of NPS. These substances, often marketed as "legal highs," can have unpredictable effects and are challenging to detect using standard screening methods [15]. The effects of these drugs can vary widely depending on factors such as dosage, individual physiology, and interactions with other substances. Common effects include:

- Sedation and loss of consciousness
- Muscle relaxation and loss of motor control
- Confusion and disorientation
- Anterograde amnesia (inability to form new memories)
- Nausea and vomiting
- Respiratory depression (in severe cases)

The combination of these effects creates a situation where victims may be unable to resist assault, may not remember the events clearly, and may experience significant physical and psychological harm [16]



Figure 1: Microfluidic paper-based analytical device (µPAD)

2. Emerging Sensor-Based Technologies

The limitations of traditional laboratory-based techniques have spurred the development of innovative sensor-based technologies for detecting club drugs. These emerging methods aim to provide rapid, portable, and user-friendly solutions for on-site detection.

2.1. Microfluidic Paper-Based Analytical Devices (μPADs)

Microfluidic Paper-Based Analytical Devices (μPADs) have emerged as a promising platform for low-cost, rapid, and portable detection of club drugs. These devices leverage the capillary action of paper to transport and mix reagents, enabling simple and efficient chemical analysis [31].

Key features of μPADs include:

- Simplicity and Cost-Effectiveness: μPADs are typically made from inexpensive materials like paper or cellulose, significantly reducing production costs [32].
- Portability: Their small size and lightweight nature make μPADs ideal for on-site testing in various settings [33].
- Multiplex Detection: Advanced μPADs can incorporate multiple detection zones, allowing for simultaneous testing of several drugs [34].
- Environmental Friendliness: The biodegradable nature of paper-based devices reduces environmental impact [35].

Recent advancements in μPADs for club drug detection include:

- Development of a μPAD for simultaneous detection of ketamine and amphetamine, utilizing colorimetric reactions visible to the naked eye [36].
- Integration of nanoparticles and aptamers into μPADs to enhance sensitivity and specificity for GHB detection [37].
- Combination of μPADs with smartphone-based image analysis for quantitative assessment of drug concentrations [38].

2.2. Electrochemical Sensors

Electrochemical sensors offer another promising approach for rapid and sensitive detection of club drugs. These sensors measure electrical signals generated by chemical reactions involving the target drugs.

Advantages of electrochemical sensors include:

- High Sensitivity: Many electrochemical methods can detect drugs at very low concentrations [39].
- Rapid Response: Results can often be obtained within minutes [40].
- Miniaturization Potential: Electrochemical sensors can be fabricated in small sizes, suitable for portable devices [41].
- Recent developments in electrochemical sensors for club drug detection include:
- Screen-printed electrodes modified with molecularly imprinted polymers for selective detection of GHB [42].
- Aptamer-based electrochemical sensors for the detection of ketamine, offering high specificity and sensitivity [43].
- Nanomaterial-enhanced electrochemical sensors, such as graphene-modified electrodes, for improved detection of benzodiazepines [44].

2.3. Colorimetric Assays and Visual Detection Methods

Colorimetric assays and visual detection methods offer simple, rapid, and often equipment-free approaches to drug detection. These methods typically involve chemical reactions that produce visible color changes in the presence of specific drugs.

Key advantages include:

- Ease of Use: Results can often be interpreted without specialized training [45].
- Rapid Results: Color changes usually occur within minutes [46].
- Low Cost: Many colorimetric tests use inexpensive reagents and materials [47].
- Recent innovations in colorimetric and visual detection methods include:
- Development of color-changing drink stirrers that react to the presence of GHB or ketamine [48].
- Nanoparticle-based colorimetric assays that aggregate in the presence of club drugs, producing visible color shifts [49].
- Integration of colorimetric tests with smartphone apps for more objective interpretation of results [50].
- Integration with Smart Technologies

a.

b.

Figure 2. **Some of other available club drugs detection kits a. Colorimetric indicators b. Paper based indicator**

2.4. Smartphone-Based Detection Systems

Smartphones have become powerful tools for on-site drug detection, offering high-resolution cameras, powerful processors, and connectivity features.

Key aspects of smartphone-based detection systems include:

- Image Analysis: Smartphone cameras can capture and analyze color changes in colorimetric tests with high precision [51].
- Data Processing: Built-in processors can perform complex calculations for quantitative analysis [52].
- Connectivity: Results can be immediately shared with relevant parties or databases [53].
- Recent developments in smartphone-based detection systems include:
- Apps that analyze images of µPADs to provide quantitative results for multiple club drugs simultaneously [54].
- Integration of external sensors, such as miniaturized spectrometers, with smartphones for enhanced detection capabilities [55].
- Development of smartphone-compatible electrochemical sensors for quantitative drug analysis [56].

2.5. Machine Learning and Data Analysis

The application of machine learning and advanced data analysis techniques has greatly improved the accuracy and reliability of club drug detection methods.

Key applications include:

- Pattern Recognition: Machine learning algorithms can identify subtle patterns in sensor data that may indicate the presence of drugs [57].
- Multivariate Analysis: Advanced statistical techniques can differentiate between complex mixtures of substances [58].
- Predictive Modeling: Machine learning models can predict the likelihood of drug presence based on multiple sensor inputs [59].

Recent advancements in this area include:

- Development of neural network models for interpreting colorimetric test results, reducing subjectivity in visual interpretation [60].
- Application of support vector machines for classifying electrochemical sensor data, improving the accuracy of drug identification [61].
- Use of deep learning algorithms to analyze spectral data from portable spectrometers, enabling detection of novel psychoactive substances [62].

3. Smartphone Based Detection Systems

3.1. Smartphone-Based Detection Systems

The ubiquity of smartphones has revolutionized the field of on-site drug detection, offering powerful computing capabilities in a portable format. Smartphone-based detection systems for club drugs leverage various features of modern mobile devices:

- High-Resolution Cameras: Modern smartphone cameras can capture detailed images of colorimetric tests or μPADs, enabling precise analysis of color changes [63]. For instance, researchers have developed apps that use image processing algorithms to quantify the concentration of GHB in drinks based on the intensity of color produced in a paper-based test [64].
- Processing Power: The computational capabilities of smartphones allow for real-time analysis of sensor data. This enables rapid interpretation of results from electrochemical sensors or spectroscopic devices connected to the phone [65].
- Connectivity: The ability to instantly share results via mobile networks facilitates rapid response in emergency situations and allows for the creation of centralized databases for tracking drug prevalence [66].
- User-Friendly Interfaces: Intuitive app designs make complex analytical procedures accessible to non-expert users, potentially expanding the use of these detection systems in social settings [67].

Recent innovations in smartphone-based detection systems include:

- Development of attachable spectrometers that convert smartphones into portable analytical devices capable of detecting multiple drugs simultaneously [68].
- Creation of smartphone-compatible electrochemical sensors that can detect trace amounts of ketamine and other club drugs in biological samples [69].
- Integration of augmented reality (AR) technology to guide users through the testing process and provide clear visual interpretations of results [70].

3.2. Machine Learning and Data Analysis

The integration of machine learning and advanced data analysis techniques with sensor-based detection methods has significantly enhanced the accuracy and reliability of club drug detection:

- Neural Networks: Deep learning models have been employed to analyze complex spectral data from portable spectrometers, enabling the identification of novel psychoactive substances that may not be detectable by traditional methods [71].
- Support Vector Machines (SVMs): SVMs have been utilized to classify electrochemical sensor data, improving the accuracy of drug identification in mixed samples [72].
- Random Forests: This ensemble learning method has been applied to interpret data from multiple sensors simultaneously, enhancing the robustness of drug detection systems [73].
- Principal Component Analysis (PCA): PCA has been used to reduce the dimensionality of spectroscopic data, allowing for more efficient processing on smartphone devices [74].

Recent advancements include:

- Development of a machine learning model that can predict the presence of GHB in beverages based on subtle changes in drink properties, such as refractive index and electrical conductivity [75].
- Application of transfer learning techniques to adapt existing drug detection models to new, emerging substances with limited training data [76].
- Implementation of federated learning approaches that allow multiple institutions to collaboratively improve drug detection algorithms without sharing sensitive data [77]

4. Challenges in Multi-Drug Detection

4.1. Cross-Reactivity and Interference

One of the primary challenges in developing reliable multi-drug detection systems is managing cross-reactivity and interference from other substances:

- Structural Similarities: Many club drugs share similar chemical structures, leading to potential false positives in detection assays. For example, GHB and GBL have similar molecular structures, making selective detection challenging [78].
- Metabolites and Precursors: Some detection methods may react to drug metabolites or precursor chemicals, complicating the interpretation of results. This is particularly problematic for drugs like GHB, which is rapidly metabolized in the body [79].
- Matrix Effects: The presence of other substances in beverages or biological samples can interfere with detection methods. For instance, certain food dyes or additives may alter the color development in colorimetric assays [80].

- Poly-drug Use: The simultaneous presence of multiple drugs can lead to complex interactions that affect the reliability of detection methods [81].

Strategies to address these challenges include:

- Development of highly specific aptamer-based sensors that can distinguish between structurally similar compounds [82].
- Implementation of multi-step detection processes that combine different analytical techniques to confirm results and reduce false positives [83].
- Incorporation of sample preparation steps, such as solid-phase extraction, to remove interfering substances before analysis [84].

4.2. Sensitivity and Specificity Considerations

Balancing sensitivity (ability to detect low concentrations) and specificity (ability to correctly identify specific drugs) is crucial for effective multi-drug detection systems:

- Detection Limits: Many club drugs are active at very low doses, requiring extremely sensitive detection methods. For example, effective doses of GHB can be as low as 1-2 g in a drink, necessitating detection limits in the mg/mL range [85].
- False Positives vs. False Negatives: Increasing sensitivity often comes at the cost of increased false positives, while prioritizing specificity may lead to false negatives. Striking the right balance is critical, especially in legal and medical contexts [86].
- Concentration Range: Detection methods must be able to accurately quantify drug concentrations across a wide range, from trace amounts to potentially lethal doses [87].
- Time Sensitivity: The rapid metabolism of many club drugs necessitates detection methods that can identify substances quickly before they are eliminated from the body [88].

Recent approaches to address these challenges include:

- Development of multiplexed sensor arrays that combine multiple detection modalities to improve both sensitivity and specificity [89].
- Implementation of machine learning algorithms that can dynamically adjust detection thresholds based on contextual information, optimizing the balance between sensitivity and specificity [90].
- Creation of time-resolved detection methods that can track changes in drug concentrations over short periods, providing more accurate assessments of drug presence and metabolism [91].

5. Legal and Ethical Considerations

5.1. Privacy Concerns

The development and implementation of advanced drug detection technologies raise significant privacy concerns:

- Data Collection and Storage: Smartphone-based detection systems often collect and store sensitive personal information. The potential for this data to be accessed by unauthorized parties or used for purposes beyond drug detection is a major concern [92].
- Consent and Autonomy: The use of these technologies in public spaces or without explicit consent raises questions about individual autonomy and the right to privacy [93].
- Stigmatization: Widespread use of drug detection technologies could lead to increased stigmatization of individuals in certain social settings or communities [94].
- Workplace Testing: The potential for employers to use these technologies for regular or random drug testing raises concerns about employee privacy rights [95].

Addressing these concerns requires:

- Implementation of robust data protection measures, including encryption and anonymization of personal information [96].
- Development of clear guidelines for obtaining informed consent before using detection technologies [97].
- Creation of policies that limit the use and retention of data collected through drug detection systems [98].

5.2. Regulatory Landscape

The regulatory environment surrounding drug detection technologies is complex and varies significantly across jurisdictions:

- Legal Admissibility: The use of results from novel detection methods as evidence in legal proceedings is not uniformly accepted across different legal systems [99].
- Standardization: Lack of standardized protocols for using and interpreting results from new detection technologies complicates their widespread adoption [100].
- Approval Processes: The path to regulatory approval for new drug detection technologies, especially those intended for medical or forensic use, can be lengthy and complex [101].
- International Variations: Differences in drug laws and regulatory frameworks across countries create challenges for the global implementation of detection technologies [102].

Recent developments in the regulatory landscape include:

- Efforts by organizations like the United Nations Office on Drugs and Crime to develop international standards for drug testing technologies [103].
- Initiatives by regulatory bodies such as the FDA to create expedited approval pathways for innovative medical devices, including drug detection technologies [104].
- Ongoing debates in various jurisdictions about the legal and ethical implications of using drug detection technologies in public spaces [105].

6. Future Perspectives

6.1. Nanotechnology in Drug Detection

Nanotechnology offers exciting possibilities for enhancing the sensitivity and specificity of drug detection methods:

- Nanoparticle-Based Sensors: Functionalized nanoparticles can be designed to interact specifically with target drugs, enabling highly sensitive detection [106].
- Nano-Engineered Surfaces: Surfaces modified at the nanoscale can enhance the capture and detection of drug molecules, improving sensitivity [107].
- Quantum Dots: These nanoscale semiconductor particles offer unique optical properties that can be exploited for ultrasensitive drug detection [108].

Emerging research in this area includes:

- Development of plasmonic nanosensors capable of detecting multiple club drugs simultaneously at extremely low concentrations [109].
- Creation of nano-bioelectronic devices that combine biological recognition elements with nanoelectronics for rapid, sensitive drug detection [110].

6.2. Wearable Sensors and Continuous Monitoring

The integration of drug detection capabilities into wearable devices offers the potential for continuous, non-invasive monitoring:

- Sweat-Based Detection: Wearable sensors that can detect drugs and their metabolites in sweat offer a non-invasive approach to continuous monitoring [111].
- Transdermal Sensors: Advanced sensors capable of detecting drugs through the skin without breaking the skin barrier are under development [112].
- Smart Jewelry: Integration of miniaturized sensors into everyday accessories like rings or bracelets could provide discreet, continuous protection [113].

Recent innovations include:

- Development of a wearable biosensor patch that can detect multiple drugs of abuse in sweat over extended periods [114].
- Creation of smart contact lenses capable of detecting drugs in tears, offering a potential avenue for continuous monitoring [115].

6.3. Biomarker-Based Approaches

Focusing on the detection of specific biological markers associated with drug use offers a promising avenue for future development:

- Metabolomics: Comprehensive analysis of metabolic changes induced by drug use could provide more accurate and long-lasting detection capabilities [116].
- Epigenetic Markers: Detection of epigenetic changes associated with drug use could offer insights into both recent and historical drug exposure [117].
- Immune Response Markers: Monitoring changes in immune system components in response to drug exposure could provide an alternative detection approach [118].

Ongoing research in this area includes:

- Identification of unique metabolic signatures associated with the use of specific club drugs, enabling more accurate and personalized detection [119].
- Development of assays targeting epigenetic modifications as long-term markers of drug exposure [120].

7. Conclusion

The field of club drug detection is rapidly evolving, driven by advances in sensor technology, smart devices, and data analysis techniques. Emerging technologies offer the promise of more rapid, accurate, and accessible detection methods, potentially revolutionizing our ability to prevent and respond to drug-facilitated crimes. However, these advancements come with significant challenges. Balancing the need for sensitive and specific detection with concerns about privacy and ethical use of these technologies remains a critical issue. The complex and evolving nature of club drugs, coupled with the need for real-time, on-site detection, continues to push the boundaries of what is technologically possible. Looking to the future, the integration of nanotechnology, wearable sensors, and biomarker-based approaches holds great promise. These innovations could lead to detection systems that are not only more accurate and sensitive but also less intrusive and more easily integrated into everyday life

References

[1] Patra S, Roy E, Karfa P, Kumar S, Madhuri R, Sharma PK. Dual-responsive polymer coated superparamagnetic nanoparticle for targeted drug delivery and hyperthermia treatment. ACS Appl Mater Interfaces. 2015;7(17):9235-46.

[2] Yetisen AK, Akram MS, Lowe CR. Paper-based microfluidic point-of-care diagnostic devices. Lab Chip. 2013;13(12):2210-51.

[3] Ribeiro MF, Júnior JC, Silva DM, et al. Development of a new microfluidic paper-based analytical device for ketamine and amphetamine detection. Anal Methods. 2019;11(48):6162-70.

[4] Liana DD, Raguse B, Gooding JJ, Chow E. Recent advances in paper-based sensors. Sensors. 2012;12(9):11505-26.

[5] Morbioli GG, Mazzu-Nascimento T, Stockton AM, Carrilho E. Technical aspects and challenges of colorimetric detection with microfluidic paper-based analytical devices (μPADs) - A review. Anal Chim Acta. 2017;970:1-22.

[6] Choi JR, Yong KW, Choi JY, Cowie AC. Emerging point-of-care technologies for food safety analysis. Sensors. 2019;19(4):817.

[7] Yang Z, Xu G, Reboud J, et al. Rapid veterinary diagnosis of bovine reproductive infectious diseases from semen using paper-origami DNA microfluidics. ACS Sens. 2018;3(2):403-9.

[8] Bueno L, de Araujo WR, Salles MO, Kussler MN, Paixão TR. Voltammetric electronic tongue for discrimination of milk adulterated with urea, formaldehyde and melamine. Chemosensors. 2014;2(4):251-66.

[9] Sekar NC, Ge L, Shaegh SA, Ng SH, Tan SN. A flow-free microfluidic device for quantifying electrochemical blocking of nanochannels. Lab Chip. 2015;15(20):4071-8.

[10] Roushani M, Shahdost-fard F. A novel ultrasensitive aptasensor based on silver nanoparticles measured via enhanced voltammetric response of electrochemical reduction of riboflavin as redox probe for cocaine detection. Sens Actuators B Chem. 2015;207:764-71.

[11] Bagheri H, Afkhami A, Khoshsafar H, Rezaei M, Shirzadmehr A. Simultaneous electrochemical determination of morphine and codeine using a reduced graphene oxide-based screen-printed electrode modified with palladium nanoparticles. RSC Adv. 2015;5(28):21659-69.

[12] Andrade FN, Santos-Neto ÁJ, Lanças FM. Microextraction by packed sorbent liquid chromatography with time-of-flight mass spectrometry of triazines herbicides in aqueous samples. J Sep Sci. 2016;39(11):2054-61.

[13] Smith JP, Sutcliffe OB, Banks CE. An overview of recent developments in the analytical detection of new psychoactive substances (NPSs). Analyst. 2015;140(15):4932-48.

[14] Cumba LR, Smith JP, Zuway KY, et al. Forensic electrochemistry: simultaneous voltammetric detection of MDMA and its fatal counterpart "Dr Death" (PMA). Anal Methods. 2016;8(1):142-52.

[15] Krauss ST, Remcho TP, Lipes SM, Aranda R, Maynard HJ, Shukla N, et al. Objective method for presumptive field-testing of illicit drug possession using centrifugal microdevices and smartphone analysis. Anal Chem. 2016;88(17):8689-97.

[16] Yu H, Tan Y, Cunningham BT. Smartphone fluorescence spectroscopy. Anal Chem. 2014;86(17):8805-13.

[17] Guo T, Gu J, Tao L, Wang S, Shen X, Wang N. A smartphone-based electrochemical platform with interchangeable enzyme-functionalized microneedle arrays for real-time multi-marker chronic disease monitoring. Sens Actuators B Chem. 2020;320:128434.

[18] Kim SC, Jalal UM, Im SB, Ko S, Shim JS. A smartphone-based optical platform for colorimetric analysis of microfluidic device. Sens Actuators B Chem. 2017;239:52-9.

[19] Li Z, Askim JR, Suslick KS. The optoelectronic nose: colorimetric and fluorometric sensor arrays. Chem Rev. 2019;119(1):231-92.

[20] Roda A, Michelini E, Zangheri M, Di Fusco M, Calabria D, Simoni P. Smartphone-based biosensors: A critical review and perspectives. TrAC Trends Anal Chem. 2016;79:317-25.

[21] Hossain SM, Ozimok C, Sicard C, et al. Multiplexed paper test strip for quantitative bacterial detection. Anal Bioanal Chem. 2012;403(6):1567-76.

[22] Shen L, Hagen JA, Papautsky I. Point-of-care colorimetric detection with a smartphone. Lab Chip. 2012;12(21):4240-3.

[23] Mei Q, Jing H, Li Y, et al. Smartphone based visual and quantitative assays on upconversional paper sensor. Biosens Bioelectron. 2016;75:427-32.

[24] Fu Q, Wu Z, Xu F, et al. A portable smart phone-based plasmonic nanosensor readout platform that measures transmitted light intensities of nanosubstrates using an ambient light sensor. Lab Chip. 2016;16(10):1927-33.

[25] Choi JR, Yong KW, Tang R, et al. Advances and challenges of fully integrated paper-based point-of-care nucleic acid testing. TrAC Trends Anal Chem. 2017;93:37-50.

[26] Lu Y, Shi W, Qin J, Lin B. Low cost, portable detection of gold nanoparticle-labeled microfluidic immunoassay with camera cell phone. Electrophoresis. 2009;30(4):579-82.

[27] Zhu H, Sikora U, Ozcan A. Quantum dot enabled detection of Escherichia coli using a cell-phone. Analyst. 2012;137(11):2541-4.

[28] Priye A, Bird SW, Light YK, Ball CS, Negrete OA, Meagher RJ. A smartphone-based diagnostic platform for rapid detection of Zika, chikungunya, and dengue viruses. Sci Rep. 2017;7(1):44778.

[29] Zhang D, Liu Q. Biosensors and bioelectronics on smartphone for portable biochemical detection. Biosens Bioelectron. 2016;75:273-84.

[30] Xu X, Akay A, Wei H, et al. Advances in smartphone-based point-of-care diagnostics. Proc IEEE. 2015;103(2):236-47.

[31] Calabria D, Caliceti C, Zangheri M, et al. Smartphone-based enzymatic biosensor for oral fluid L-lactate detection in one minute using confined multilayer paper reflectometry. Biosens Bioelectron. 2017;94:124-30.

[32] Ganguli A, Ornob A, Yu H, et al. Hands-free smartphone-based diagnostics for simultaneous detection of Zika, Chikungunya, and Dengue at point-of-care. Biomed Microdevices. 2017;19(4):73.

[33] Lillehoj PB, Huang MC, Truong N, Ho CM. Rapid electrochemical detection on a mobile phone. Lab Chip. 2013;13(15):2950-5.

[34] Quesada-González D, Merkoçi A. Mobile phone-based biosensing: An emerging "diagnostic and communication" technology. Biosens Bioelectron. 2017;92:549-62.

[35] Vashist SK, Luppa PB, Yeo LY, Ozcan A, Luong JH. Emerging technologies for next-generation point-of-care testing. Trends Biotechnol. 2015;33(11):692-705.

[36] Zhu H, Isikman SO, Mudanyali O, Greenbaum A, Ozcan A. Optical imaging techniques for point-of-care diagnostics. Lab Chip. 2013;13(1):51-67.

[37] Kumar AA, Hennek JW, Smith BS, et al. From the bench to the field in low-cost diagnostics: two case studies. Angew Chem Int Ed Engl. 2015;54(20):5836-53.

[38] Martinez AW, Phillips ST, Whitesides GM, Carrilho E. Diagnostics for the developing world: microfluidic paper-based analytical devices. Anal Chem. 2010;82(1):3-10.

[39] Mao X, Huang TJ. Microfluidic diagnostics for the developing world. Lab Chip. 2012;12(8):1412-6.

[40] Chin CD, Linder V, Sia SK. Commercialization of microfluidic point-of-care diagnostic devices. Lab Chip. 2012;12(12):2118-34.

[41] Urdea M, Penny LA, Olmsted SS, et al. Requirements for high impact diagnostics in the developing world. Nature. 2006;444(Suppl 1):73-9.

[42] Yager P, Domingo GJ, Gerdes J. Point-of-care diagnostics for global health. Annu Rev Biomed Eng. 2008;10:107-44.

[43] Dungchai W, Chailapakul O, Henry CS. Electrochemical detection for paper-based microfluidics. Anal Chem. 2009;81(14):5821-6.

[44] Nie Z, Nijhuis CA, Gong J, et al. Electrochemical sensing in paper-based microfluidic devices. Lab Chip. 2010;10(4):477-83.

[45] Adkins J, Boehle K, Henry C. Electrochemical paper-based microfluidic devices. Electrophoresis. 2015;36(16):1811-24.

[46] Mettakoonpitak J, Boehle K, Nantaphol S, et al. Electrochemistry on paper-based analytical devices: a review. Electroanalysis. 2016;28(7):1420-36.

[47] Smith JP, Metters JP, Khreit OI, Sutcliffe OB, Banks CE. Forensic electrochemistry applied to the sensing of new psychoactive substances: electroanalytical sensing of synthetic cathinones and analytical validation in the quantification of seized street samples. Anal Chem. 2014;86(19):9985-92.

[48] Teengam P, Siangproh W, Tuantranont A, et al. Multiplex paper-based colorimetric DNA sensor using pyrrolidinyl peptide nucleic acid-induced AgNPs aggregation for detecting MERS-CoV, MTB, and HPV oligonucleotides. Anal Chem. 2017;89(10):5428-35.

[49] Chaiyo S, Siangproh W, Apilux A, Chailapakul O. Highly selective and sensitive paper-based colorimetric sensor using thiosulfate catalytic etching of silver nanoplates for trace determination of copper ions. Anal Chim Acta. 2015;866:75-83.

[50] Pena-Pereira F, Lavilla I, Bendicho C. Paper-based analytical device for instrumental-free detection of thiocyanate in saliva as a biomarker of tobacco smoke exposure. Talanta. 2016;147:390-6.

[51] Mentele MM, Cunningham J, Koehler K, Volckens J, Henry CS. Microfluidic paper-based analytical device for particulate metals. Anal Chem. 2012;84(10):4474-80.

[52] Nilghaz A, Wicaksono DH, Gustiono D, et al. Flexible microfluidic cloth-based analytical devices using a low-cost wax patterning technique. Lab Chip. 2012;12(1):209-18.

[53] Abe K, Suzuki K, Citterio D. Inkjet-printed microfluidic multianalyte chemical sensing paper. Anal Chem. 2008;80(18):6928-34.

[54] Martinez AW, Phillips ST, Butte MJ, Whitesides GM. Patterned paper as a platform for inexpensive, low-volume, portable bioassays. Angew Chem Int Ed Engl. 2007;46(8):1318-20.

[55] Carrilho E, Martinez AW, Whitesides GM. Understanding wax printing: a simple micropatterning process for paper-based microfluidics. Anal Chem. 2009;81(16):7091-5.

[56] Määttänen A, Fors D, Wang S, et al. Paper-based planar reaction arrays for printed diagnostics. Sens Actuators B Chem. 2011;160(1):1404-12.

[57] Li X, Tian J, Shen W. Progress in patterned paper sizing for fabrication of paper-based microfluidic sensors. Cellulose. 2010;17(3):649-59.

[58] Olkkonen J, Lehtinen K, Erho T. Flexographically printed fluidic structures in paper. Anal Chem. 2010;82(24):10246-50.

[59] Bruzewicz DA, Reches M, Whitesides GM. Low-cost printing of poly(dimethylsiloxane) barriers to define microchannels in paper. Anal Chem. 2008;80(9):3387-92.

[60] Lu Y, Shi W, Jiang L, Qin J, Lin B. Rapid prototyping of paper-based microfluidics with wax for low-cost, portable bioassay. Electrophoresis. 2009;30(9):1497-500

[61] Yamada K, Henares TG, Suzuki K, Citterio D. Paper-based inkjet-printed microfluidic analytical devices. Angew Chem Int Ed Engl. 2015;54(18):5294-310.

[62] Cate DM, Adkins JA, Mettakoonpitak J, Henry CS. Recent developments in paper-based microfluidic devices. Anal Chem. 2015;87(1):19-41.

[63] Yetisen AK, Akram MS, Lowe CR. Paper-based microfluidic point-of-care diagnostic devices. Lab Chip. 2013;13(12):2210-51.

[64] Xia Y, Si J, Li Z. Fabrication techniques for microfluidic paper-based analytical devices and their applications for biological testing: A review. Biosens Bioelectron. 2016;77:774-89.

[65] Akyazi T, Basabe-Desmonts L, Benito-Lopez F. Review on microfluidic paper-based analytical devices towards commercialisation. Anal Chim Acta. 2018;1001:1-17.

[66] Xu Y, Liu M, Kong N, Liu J. Lab-on-paper micro- and nano-analytical devices: Fabrication, modification, detection and emerging applications. Microchim Acta. 2016;183(5):1521-42.

[67] Li X, Ballerini DR, Shen W. A perspective on paper-based microfluidics: Current status and future trends. Biomicrofluidics. 2012;6(1):011301.

[68] Nery EW, Kubota LT. Sensing approaches on paper-based devices: a review. Anal Bioanal Chem. 2013;405(24):7573-95.

[69] Parolo C, Merkoçi A. Paper-based nanobiosensors for diagnostics. Chem Soc Rev. 2013;42(2):450-7.

[70] Hu J, Wang S, Wang L, et al. Advances in paper-based point-of-care diagnostics. Biosens Bioelectron. 2014;54:585-97.

[71] Narla D, Thummala UK. Orodispersible Films for Enhanced Bioavailability of Carvedilol. Journal of Pharma Insights and Research. 2024 Apr 28;2(2):236-44.

[72] Gubala V, Harris LF, Ricco AJ, Tan MX, Williams DE. Point of care diagnostics: status and future. Anal Chem. 2012;84(2):487-515.

[73] Yager P, Edwards T, Fu E, et al. Microfluidic diagnostic technologies for global public health. Nature. 2006;442(7101):412-8.

[74] Chin CD, Linder V, Sia SK. Lab-on-a-chip devices for global health: past studies and future opportunities. Lab Chip. 2007;7(1):41-57.

[75] Sharma S, Zapatero-Rodríguez J, Estrela P, O'Kennedy R. Point-of-care diagnostics in low resource settings: present status and future role of microfluidics. Biosensors. 2015;5(3):577-601.

[76] Peeling RW, Holmes KK, Mabey D, Ronald A. Rapid tests for sexually transmitted infections (STIs): the way forward. Sex Transm Infect. 2006;82 Suppl 5:v1-6.

[77] Posinasetty B, Madhu C, Galgatte UC, Kommineni S, Basavaraj H, Rao BA, Narla D, Ande SN. Design and Evaluation of Polyherbal Nanogel for The Treatment of Rheumatoid Arthritis. Journal of Advanced Zoology. 2023 Sep 4;44.

[78] Cheng CM, Martinez AW, Gong J, et al. Paper-based ELISA. Angew Chem Int Ed Engl. 2010;49(28):4771-4.

[79] Fu E, Liang T, Spicar-Mihalic P, et al. Two-dimensional paper network format that enables simple multistep assays for use in low-resource settings in the context of malaria antigen detection. Anal Chem. 2012;84(10):4574-9.

[80] Murdock RC, Shen L, Griffin DK, et al. Optimization of a paper-based ELISA for a human performance biomarker. Anal Chem. 2013;85(23):11634-42.

[81] Wang S, Ge L, Song X, et al. Paper-based chemiluminescence ELISA: lab-on-paper based on chitosan modified paper device and wax-screen-printing. Biosens Bioelectron. 2012;31(1):212-8.

[82] Zhao W, Ali MM, Aguirre SD, Brook MA, Li Y. Paper-based bioassays using gold nanoparticle colorimetric probes. Anal Chem. 2008;80(22):8431-7.

[83] Li CZ, Vandenberg K, Prabhulkar S, et al. Paper based point-of-care testing disc for multiplex whole cell bacteria analysis. Biosens Bioelectron. 2011;26(11):4342-8.

[84] Fenton EM, Mascarenas MR, López GP, Sibbett SS. Multiplex lateral-flow test strips fabricated by two-dimensional shaping. ACS Appl Mater Interfaces. 2009;1(1):124-9.

[85] Apilux A, Ukita Y, Chikae M, Chailapakul O, Takamura Y. Development of automated paper-based devices for sequential multistep sandwich enzyme-linked immunosorbent assays using inkjet printing. Lab Chip. 2013;13(1):126-35.

[86] Liang J, Wang Y, Liu B. Paper-based fluoroimmunoassay for rapid and sensitive detection of antigen. RSC Adv. 2012;2(9):3878-84.

[87] Zhu WJ, Feng DQ, Chen M, Chen ZD, Zhu R, Fang HL, Wang W. Bienzyme colorimetric detection of glucose with self-calibration based on tree-shaped paper strip. Sens Actuators B Chem. 2014;190:414-8.

[88] Sechi D, Greer B, Johnson J, Hashemi N. Three-dimensional paper-based microfluidic device for assays of protein and glucose in urine. Anal Chem. 2013;85(22):10733-7.

[89] Rattanarat P, Dungchai W, Cate D, et al. Multilayer paper-based device for colorimetric and electrochemical quantification of metals. Anal Chem. 2014;86(7):3555-62.

[90] Nie Z, Deiss F, Liu X, Akbulut O, Whitesides GM. Integration of paper-based microfluidic devices with commercial electrochemical readers. Lab Chip. 2010;10(22):3163-9

[91] Dungchai W, Chailapakul O, Henry CS. Use of multiple colorimetric indicators for paper-based microfluidic devices. Anal Chim Acta. 2010;674(2):227-33.

[92] Shen L, Hagen JA, Papautsky I. Point-of-care colorimetric detection with a smartphone. Lab Chip. 2012;12(21):4240-3.

[93] Lopez-Ruiz N, Curto VF, Erenas MM, et al. Smartphone-based simultaneous pH and nitrite colorimetric determination for paper microfluidic devices. Anal Chem. 2014;86(19):9554-62.

[94] Oncescu V, O'Dell D, Erickson D. Smartphone based health accessory for colorimetric detection of biomarkers in sweat and saliva. Lab Chip. 2013;13(16):3232-8.

[95] Yetisen AK, Martinez-Hurtado JL, Garcia-Melendrez A, da Cruz Vasconcellos F, Lowe CR. A smartphone algorithm with inter-phone repeatability for the analysis of colorimetric tests. Sens Actuators B Chem. 2014;196:156-60.

[96] Mudanyali O, Dimitrov S, Sikora U, Padmanabhan S, Navruz I, Ozcan A. Integrated rapid-diagnostic-test reader platform on a cellphone. Lab Chip. 2012;12(15):2678-86.

[97] Vashist SK, van Oordt T, Schneider EM, Zengerle R, von Stetten F, Luong JH. A smartphone-based colorimetric reader for bioanalytical applications using the screen-based bottom illumination provided by gadgets. Biosens Bioelectron. 2015;67:248-55.

[98] Sarella PN, Vegi S, Vendi VK, Vipparthi AK, Valluri S. Exploring Aquasomes: A Promising Frontier in Nanotechnology-based Drug Delivery. Asian Journal of Pharmaceutical Research. 2024 May 28;14(2):153-61.

[99] Nemiroski A, Christodouleas DC, Hennek JW, et al. Universal mobile electrochemical detector designed for use in resource-limited applications. Proc Natl Acad Sci U S A. 2014;111(33):11984-9.

[100] Sun A, Wambach T, Venkatesh AG, Hall DA. A low-cost smartphone-based electrochemical biosensor for point-of-care diagnostics. IEEE Biomed Circuits Syst Conf. 2014;2014:312-5.

[101] Guo J. Smartphone-powered electrochemical dongle for point-of-care monitoring of blood β-ketone. Anal Chem. 2017;89(17):8609-13.

[102] Chin CD, Linder V, Sia SK. Commercialization of microfluidic point-of-care diagnostic devices. Lab Chip. 2012;12(12):2118-34.

[103] Yetisen AK, Akram MS, Lowe CR. Paper-based microfluidic point-of-care diagnostic devices. Lab Chip. 2013;13(12):2210-51.

[104] Martinez AW, Phillips ST, Whitesides GM, Carrilho E. Diagnostics for the developing world: microfluidic paper-based analytical devices. Anal Chem. 2010;82(1):3-10.

[105] Fu E, Liang T, Houghtaling J, et al. Enhanced sensitivity of lateral flow tests using a two-dimensional paper network format. Anal Chem. 2011;83(20):7941-6.

[106] Mangam VT, Narla D, Konda RK, Sarella PN. Beyond the spectrum: Exploring unconventional applications of fourier transform infrared (FTIR) spectroscopy. Asian Journal of Pharmaceutical Analysis. 2024;14(2):86-94.

[107] Li X, Ballerini DR, Shen W. A perspective on paper-based microfluidics: Current status and future trends. Biomicrofluidics. 2012;6(1):011301.

[108] Sarkar S, Manna S, Das S, De S, Paul P, Dua TK, Sahu R, Nandi G. Current Status of Marine Animal Derived Polysaccharides in Sustainable Food Packaging. ACS Food Science & Technology. 2023;3(11):1877-1889.

[109] Parolo C, Merkoçi A. Paper-based nanobiosensors for diagnostics. Chem Soc Rev. 2013;42(2):450-7.

[110] Yager P, Edwards T, Fu E, et al. Microfluidic diagnostic technologies for global public health. Nature. 2006;442(7101):412-8.

[111] Sia SK, Linder V, Parviz BA, Siegel A, Whitesides GM. An integrated approach to a portable and low-cost immunoassay for resource-poor settings. Angew Chem Int Ed Engl. 2004;43(4):498-502.

[112] Martinez AW, Phillips ST, Carrilho E, Thomas SW 3rd, Sindi H, Whitesides GM. Simple telemedicine for developing regions: camera phones and paper-based microfluidic devices for real-time, off-site diagnosis. Anal Chem. 2008;80(10):3699-707.

[113] Weaver AA, Reiser H, Barstis T, et al. Paper analytical devices for fast field screening of beta lactam antibiotics and antituberculosis pharmaceuticals. Anal Chem. 2013;85(13):6453-60.

[114] Pollock NR, Rolland JP, Kumar S, et al. A paper-based multiplexed transaminase test for low-cost, point-of-care liver function testing. Sci Transl Med. 2012;4(152):152ra129.

[115] Gubala V, Harris LF, Ricco AJ, Tan MX, Williams DE. Point of care diagnostics: status and future. Anal Chem. 2012;84(2):487-515.

[116] Yetisen AK, Akram MS, Lowe CR. Paper-based microfluidic point-of-care diagnostic devices. Lab Chip. 2013;13(12):2210-51.

[117] Xu X, Akay A, Wei H, et al. Advances in smartphone-based point-of-care diagnostics. Proc IEEE. 2015;103(2):236-47.

[118] Vashist SK, Luppa PB, Yeo LY, Ozcan A, Luong JH. Emerging technologies for next-generation point-of-care testing. Trends Biotechnol. 2015;33(11):692-705.

[119] Sher M, Zhuang R, Demirci U, Asghar W. Paper-based analytical devices for clinical diagnosis: recent advances in the fabrication techniques and sensing mechanisms. Expert Rev Mol Diagn. 2017;17(4):351-66.

[120] Xia Y, Si J, Li Z. Fabrication techniques for microfluidic paper-based analytical devices and their applications for biological testing: A review. Biosens Bioelectron. 2016;77:774-89.